SFCE METRO-01 four-drug metronomic regimen phase II trial for pediatric extracranial tumor.
Fiche publication
Date publication
mars 2019
Journal
Pediatric blood & cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Pr CHASTAGNER Pascal
Tous les auteurs :
Heng-Maillard MA, Verschuur A, Aschero A, Dabadie A, Jouve E, Chastagner P, Leblond P, Aerts I, De Luca B, André N
Lien Pubmed
Résumé
To investigate the antitumor activity of a four-drug metronomic chemotherapy (MC) regimen in relapsed/progressing pediatric extracranial solid tumors (EST). The primary objective was clinical benefit (complete response /partial response/stable disease [SD]) after two cycles of therapy (four months).
Référence
Pediatr Blood Cancer. 2019 Mar 28;:e27693